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ABSTRACT
With increasing age, individuals begin to experience cognitive decline, especially
memory deficits. Given the lack of effective treatments for memory loss, a new
promising approach includes targeting second messenger systems that play a critical role
in cognitive processes by inhibiting phosphodiesterases (PDEs), specifically PDE11A
since its expression is restricted to the brain. PDE11A is responsible for regulating levels
of second messengers, such as cyclic AMP and cyclic GMP, which participate in several
biochemical processes relating to long term memory function. Since these signaling
cascades are controlled by PDEs that result in turning off the signaling pathway,
inhibiting phosphodiesterases will lead to an elevated level of cyclic nucleotides and in
turn restore memory function. Based on a PDE11A inhibitor identified during an initial
screening, a variety of bisamide and sulfonamide analogs were synthesized to test if they
have improved potency and selectivity for PDE11A. Given the limited information
regarding the structure activity relationship, this data provided insight on the structure
affects the biological activity.
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Introduction
For decades, statistics have shown that with increasing age comes the possibility
of developing cognitive impairment, specifically effects on memory or language. The
mechanism of cognitive impairment is not yet fully understood seeing as each case varies
in symptom severity (1). Studies have shown associative long-term memories (aLTMs)
are more susceptible than recognition memories for individual items (rLTMs) (2).
Associative long-term memories are associated with verbal along with non-verbal stimuli
such as faces and names. Many people experience memory deficits as there is no drug
capable of counteracting or reversing the effect so exploring an alternative hypothesis is
essential. This new approach involves inhibiting phosphodiesterase 11A (PDE11A) thus
increasing the intracellular levels of second messengers such as cyclic AMP (cAMP) and
cyclic GMP (cGMP) responsible for signaling pathways involved in long term memory
function. Given that PDE11A is largely expressed in the ventral hippocampus in mice and
human brain, it provides a starting point for the discovery of an inhibitor that prevents or
reverses age related cognitive decline of aLTMs (3, 4). Inhibition of the enzyme will lead
to elevated levels of intracellular cyclic nucleotides, thereby restoring and/or enhancing
cellular function in this brain region.
Phosphodiesterase enzymes (PDEs) catalyze a hydrolysis reaction converting a
cyclic nucleotide into a nucleoside monophosphate. These enzymes function by
activating a molecule of water to hydrolyze the 3’,5’-cyclic phosphodiester bond in the
cyclic nucleotide to yield a nucleoside monophosphate. More specifically, once
nucleophilic activation of water occurs, a SN2 displacement follows at the phosphorus
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atom cleaving the phosphate ester bond. Each phosphodiesterase enzyme consists of a Cterminal catalytic domain, an N-terminal regulatory domain, and a COOH terminus. The
catalytic domain consists of a highly conserved amino acid sequence, HD(X2)H(X4)N,
which also includes cations Zn2+ and Mg2+ binding domains. On the other hand, the Nterminal amino acid sequence varies significantly amongst different isoforms. The
variation within the regulatory domain is speculated to be responsible for the difference
in function of each isoform of the enzyme. For example, PDE1 consists of a calmodulin
binding domain while GAF regulatory domains that are involved in cGMP binding are
found in PDE11 (5).
Intracellular second messengers such as cyclic AMP (cAMP) and cyclic GMP
(cGMP) are required to transmit information from neurotransmitters that bind to cell
surface receptors (6). PDEs regulate these second messengers which, in turn, regulate
various functions within and between cells (5). For example, cyclic nucleotides regulate
proliferation and differentiation, as well as cognitive functions. Phosphodiesterases are
responsible for regulating phosphorylation by protein kinases as well as controlling the
rate of cyclic nucleotide hydrolysis, thus controlling substrate availability. Additionally,
second messengers are highly significant signaling molecules that are released by cells in
response to specific stimuli such as the release of nitric oxide or the activation of Gprotein coupled receptors. Inhibition of the enzyme would directly result in a rise in the
levels of cyclic nucleotides leading to an improved response to stimuli and signaling.
This is expected since the product of the enzymatic reaction is inactive as a second
messenger resulting in termination of the signaling pathways.
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There are eleven known types of mammalian phosphodiesterase enzymes (PDE1 PDE11) (5). Each subfamily may consist of multiple isoforms that are identified using a
capital letter. The enzymes specific to cAMP include PDE4, PDE7, and PDE8 while
cGMP specific enzymes include PDE5, PDE6, and PDE9. The remainder of the enzymes
process both cAMP and cGMP, with certain preferences for one messenger over the other.
PDE11 consists of a single gene that is spliced into four variants, PDE11A1 to PDE11A4,
all of which process both types of second messengers. The amino terminal domain is
responsible for catalytic function, and contains two GAF domains alongside two
phosphorylation sites. The GAF-A domain is responsible for binding to cGMP while
GAF-B domain is required for homodimerization. Two serine residues (S117 and S162.)
found only in the PDE11A4 isoform are phosphorylated by cAMP dependent protein
kinase (PKA) and cGMP dependent protein kinase (PKG), which are speculated to play a
significant role of regulation of this enzyme. Evidence shows that if both sites are
phosphorylated, the GAF domain has an increase in affinity for cGMP, possibly due to a
conformational change occurring (7).
The PDE11 subfamily is mainly expressed in skeletal muscle, prostate, and brain
cells but the focus at hand is on PDE11A4, the longest isoform, which is solely expressed
within human brain cells. This isoform is found to be
approximately 95% homologous across mouse, rat, and
human cells (9). According to a study done on rodents
by the Kelly lab, the is found in the VHIPP (ventral
Figure 1. PDE11A4 mRNA

hippocampal formation) with 3-10 fold enrichment expression in rodent cells (7, 8).

10
when compared to expression in DHIPP (dorsal hippocampal formation), making this a
unique drug target since the hippocampal is an essential structure in associate long term
memories (Figure 1) (7). Rodent mRNA expression studies show PDE11A4 is found in
ventral hippocampal formation within neurons of CA1, subiculum, and the adjacently
connected amygdalohippocampal area with only the nervous system showing a signal for
PDE11A4. Studies have demonstrated how cAMP and cGMP singling is reduced in older
and demented hippocampus’ of rodents as well as humans as seen in Figure 2 (10, 11).
Taking everything into account, it is possible to target PDE11A4 without affecting
signaling in other regions of the brain therefore solely reestablishing cyclic nucleotide
signaling.

Figure 2. Hippocampal PDE11A expression is increased in A) Old
vs. young mice, B) adult (18-40yrs) vs. prenatal humans, and C)
demented vs. non-demented aged humans (>75yrs) (10, 11).
Currently, there are only a select few inhibitors that specifically target PDE11A,
quantifying the significance of the research project at hand (Figure 3). A screening was
completed on approximately 200,000 compounds for PDE11 inhibitors where three
compounds were identified as PDE11 inhibitors based on their structure activity
relationship: anthranilamide 1, pyridopyrazole 2, and pyrimidinyl pyrrole 3 (12).
Additionally, separate studies have been done on tadalafil 4, sildenafil 5, and vardenafil 6
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which are PDE5 inhibitors
that also have the capability
of inhibiting the PDE11A
where tadalafil was shown to
be the most potent inhibitor
with an IC50 of 73 nM (12).
In addition, dipyridamole 7
and E4021 8 are also
relatively potent PDE11
inhibitors with cAMP and cGMP as substrates with an IC50 of 0.8 μM and 1.8 μM when
studied with PDE11A3 and PDE11A4 (13). As for the project at hand, in order to analyze
the biological activity of the synthesized compounds as inhibitors, a 5-fluoro-orotic acid
growth assay was utilized. The 5FOA growth assay was proven to provide accurate
results for PDE4, PDE7, PDE8, and PDE11A inhibitors (14 - 16). This yeast-based assay
is advantageous for mammalian cells since it analyzes the growth behavior of the yeast
strains which in turn correlates to the activity of PDEs. Compounds that respond well in
this assay as PDE inhibitors are cell permeable, an important feature essential for
PDE11A inhibitors, do not interact with other yeast proteins, and are chemically stable
since the growth period is measured up to 48 hours after incubation.
The three compounds identified in this screen as PDE11A inhibitors, are
anthranilamide 1, pyridopyrazole 2, and pyrimidinyl pyrrole 3. The bisamide compound 1
was determined to be a more potent PDE11A inhibitor with an IC50 of 10 nM as well as a
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PDE10A inhibitor, whereas pyridopyrazole 2 and pyrimidinyl pyrrole 3 are more
selective PDE11 inhibitors with an IC50 of 180 nM and 110 nM. It is worth noting the
difference in selectivity of the above PDE11A inhibitors, compared to inhibition of
PDE10A. For instance, 1 is considered a dual PDE11/PDE10 inhibitor since it exhibits an
IC50 of 2 µM for PDE10A and 2 displays an IC50 of 35 µM for PDE10A. (14, 17). Hence,
PDE11A inhibitors synthesized must also be tested for PDE10 inhibition. All three
compounds have acceptable molecular weights, total polar surface area (TPSA) values
less than 90, and the potential for central nervous system permeability based on an
MDCK-1 assay. Anthranilamide 1 and pyridopyrazole 2 also show low to moderate water
solubility with inadequate metabolic stability. On the other hand, pyrimidinyl pyrrole 3
has poor water solubility but sufficient metabolic stability. As for the cLogP values,
compound 1 presented an ideal value of 3.64 however compound 2 and 3 had values of
5.33 and 6.78. These features are important in order to establish the compounds ability to
permeate the blood brain barrier where very tight cellular spacing limits paracellular
permeability, both molecular weight and TPSA should be minimized to the extent
possible. The partition coefficient between n-octanol and water, cLogP, is utilized to
gather information about the compound’s hydrophilicity to give further insight on cell
absorption and permeation.
Given the above characteristics and structure of each compound, each one allows
for optimization at multiple sites. Compound 1 was investigated alongside analogs with
various substituents in position R as seen in Figure 6. PDE11A inhibition activity
observed for both analogs (1a) and (1b) had IC50 values of 50 nM and 10 nM. In contrast,
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when testing compound 3 analogs, PDE11A inhibition activity displayed for (3a) and
(3b) had IC50 values less than 0.2 μM. The data from the 5FOA assays presented
evidence for structure activity between the substrate and enzyme leading to the
conclusion that analogs based on the structures at hand will provide key starting points
for synthesis of a biologically active molecule capable of PDE11A inhibition.

Figure 4. 5FOA and in vitro assays of 1 and derivatives.

Figure 5. 5FOA and in vitro assays of 3 and derivatives.
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Research Plan
The key aim of this research project is to provide the foundation of a PDE11A
inhibitor that is both potent along with highly selective. Due to the fact that molecules
active against PDE11A for cognitive effects will have to efficiently penetrate the blood
brain barrier, molecular characteristics play an important role in compound design. These
characteristics include molecular weight [generally < 400 g/mol], total polar surface area
(TPSA) [≤ 90 Å], cLogP [≤ 3.5], and efflux ratio (reflecting the ability of the compound
to be actively pumped out of the CNS) [MDCK ratio ~1:1]. These features will give
insight on a compounds potential for cell absorption and permeation.
This research
will

focus

on

anthranilamide 1 since
it is the most potent
P D E 11 A i n h i b i t o r
identified in the screen and because there is little available structure activity information.
The anthranilamide 1 also has favorable characteristics including a molecular weight of
370 g/mol, cLogP of 3.64, and a TPSA of 74 with potential for brain permeability. Since
1 is considered a dual PDE11/PDE10 inhibitor, the modifications will need to be assessed
for improvement of PDE11 selectivity as well as metabolic stability. Optimization of
bisamide will occur with manipulations in positions R1 and R2 as seen in Figure 6. In
position R1 various primary and secondary amines will be applied that consist of
heterocyclic compounds such as piperidine and pyrazine (Figure 7). Implementing these
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specific types of amines will aid in
understanding whether structures
similar to the methylbenzimidazole
in the original compound affects
activity of the enzyme. It is
anticipated that tertiary amide
analogs would be less susceptible to hydrolysis while on the other hand the removal of an
H-bond donor may enhance brain penetration. However, as for position R2 a variety of
benzene derivatives such as substituted phenyl heterocycles will be applied.
Synthesis of anthranilamide analogs can be carried out beginning with isatoic
anhydride 9 reacting with an amine followed by amide formation using an acid chloride.
Another straightforward route for amide formation that can be explored begins with an
ortho-nitro acid chloride 11 reacted with an amine. This will be followed by a nitro
reduction and acylation as shown in Figure 8. The modifications will permit us to
compare how primary, secondary, and sterically hindered amines improve selectivity and
also metabolic stability.

As an alternative to bisamide analogs, we plan to explore sulfonamide derivatives
because of their improved stability to hydrolysis and hydrogen bonding potential. In this
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case, the reaction mechanism will be fairly similar to those previously explained. Once
again, reactions will be carried out starting with isatoic anhydride 9 with the addition of
an amine, followed by sulfonamide formation using a sulfonyl chloride rather than an
acid chloride (Figure 9). As
drawn out in Figure 10, the
second amide carbonyl
position will be substituted
with a sulfonamide by reacting
a 2-nitrobenzenesulfonyl
chloride 13 with an amine of
choice initially. Once the
desired product is synthesized,
a nitro reduction followed by
an acylation should derive the desired sulfonamide derivative. This will permit a direct
comparison of SAR between a single functional group change, amide versus Nsulfonamide derivatives. This specific relationship analysis can only be achieved by using
the primary amine from the anthranilamide 1, 2-amino-1-methylbenzimidazole in
synthesizing both compounds, 12 and 14. Following this, amines listed in Figure 7 will
then be implemented to assess the second key region for SAR.
All compounds will be tested for PDE11A inhibition using the previously
described fission yeast-based 5FOA growth assay used to identify lead PDE11A
inhibitors. Initially, the compounds will be tested in a dose response at final
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concentrations 0.5 to 62.5 µM, however the range may change depending on the
development of potent analogs. Simultaneously, each compound will be tested against
counter-screening strains that express either PDE5A or PDE10A based on prior studies
revealing cross-reactivity from PDE11A lead inhibitors. Based upon the data in Figure 6,
the standard OD600 range for DMSO treated cells is ~0.2 opposed to ~1.2 for PDE
inhibited cells. An ED50 will be assigned based on the concentration of the compound
required to generate an OD600 of 0.7. If compounds display an ED50 <2µM for PDE11A
and >62.5µM for PDE5A and PDE10A, each will undergo further analysis by 5FOA
assays using yeast strains that express PDE1C, PDE2A, PDE3B, PDE4D, PDE7A,
PDE8A, and PDE9A. Moreover, if a compound shows no activity against PDEs (e.g. the
ED50 values >62.5µM) except for PDE11A then it will be evaluated via in vitro enzyme
assays to measure IC50 values. Those compounds with IC50 values against PDE11A <50
nM will advance to ADME property evaluation.
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Synthesis of Amide and Sulfonamide Analogs
Synthesis of anthranilamide 1 analogs first started with modifications in position
R1 to analyze the SAR using a variety of amines. A two-step scheme was carried out
beginning with the conversion of a carboxylic acid to an acid chloride (Figure 11). The
reaction of 2-benzamidobenzoic acid 15 with oxalyl chloride in methylene chloride
substituted the hydroxyl group with a chloride ion to form an acid chloride. In the
following step, the desired
product, 2-benzamidobenzoyl
chloride 16 was directly treated
with 4-phenylpiperidine and
triethylamine in DMF resulting in
N-(2-(4-phenylpiperidine-1carbonyl)phenyl)benzamide 17.
Based on the success of this
reaction, similar steps were repeated for various primary and secondary amines (Figure
12). The only difference in synthesizing the remainder of the bisamide analogs (18-23)
using amines in Figure 12, was the use of acetonitrile rather than N,Ndimethylformamide (DMF) for ease of workup. Every compound was analyzed by 1H
NMR to confirm that the desired product was synthesized. Based on this analysis,
reaction products were submitted for biological testing by our collaborator at Boston
College.
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As mentioned above,
identifying bicyclic heterocyclic
amines that could substitute for 2amino-1-methylbenzimidazole was
one of the goals to be achieved during
the project. In Figure 13, the four primary amines shown were explored in synthesis of
both bisamide and sulfonamide analogs. These amines were investigated for preparation
of bisamide derivatives. In the same manner as above, all four acylation reactions were
attempted in identical conditions. Despite the fact that all previous reactions were
successful, in this case, only acylation with 2-aminobenzothiazole (24) was effective.
Based on TLC analysis, no product formation occurred when reacting the acid chloride
with 1-methylindazol-3-amine, 2-aminobenzoxazole, or 1,2-benzisoxazol-3-amine. The
lower reactivity of these amines might stem from their low nucleophilicity. For instance,
2-aminobenzoxazole and 1,2-benzisoxazol-3-amine have increased electronegativity
making these amines less nucleophilic whereas 2-aminobenzothiazole is less
electronegative making it more nucleophilic which coincides with the results of the
reactions.
While detailed study of reaction conditions suitable for these heterocyclic amines
was not carried out, alternative routes with other starting material were briefly evaluated
using isatoic and phthalic anhydride. Isatoic anhydride has been widely used for
preparation of heterocyclic amides, but unfortunately, none of the amines reacted in
toluene or dioxane at elevated temperature.
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In a final attempt to
prepare bisamide analogs, a
three-step scheme (Figure 14)
was investigated beginning
with

2-aminoindan

hydrochloride and 2nitrobenzoyl chloride 11 in pyridine to give N-(2,3-dihydro-1H-inden-2-yl)-2nitrobenzamide 25 as the acylation product in the first step. Considering pyridine is a
moderate nucleophile for carbonyl groups, it was used as a catalyst in the acylation step.
More specifically, the nitrogen atom in pyridine is nucleophilic since the lone pair of
electrons on nitrogen are not delocalized around the ring. In the following step, catalytic
hydrogenation reduced the aromatic nitro group to an aniline. In the final step of this
synthetic route, nucleophilic addition/elimination of 2-amino-N-(2,3-dihydro-1Hinden-2-yl)benzamide with benzoyl chloride 26 resulting in the final bisamide analog, 2benzamido-N-(2,3-dihydro-1H-inden-2-yl)benzamide 27, was successfully produced and
prepared for further testing.
Simultaneously while
identifying synthetic routes
that work effectively for
generating bisamide analogs,
synthetic routes useful for
sulfonamido derivatives were
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also explored using similar starting material as shown in Figure 15. The first step
involved sulfonamide formation using 2-nitrobenzenesulfonyl chloride 13 and 2amino-1-methylbenzimidazole in chloroform with triethylamine and DMAP added as a
catalyst, successfully producing 28. This was followed by catalytic reduction of the
aromatic nitro group to an aniline in acetic acid. Solubility of this compound was initially
troublesome as it would not fully dissolve in methanol or ethanol leading to the use of a
more polar solvent such as acetic acid with the final hydrogenation product being an
acetate salt 29. Once again, the last step encompasses amide formation from nucleophilic
addition/elimination with benzoyl chloride to give the sulfonamide derivative 30. A
similar approach with slightly different reaction conditions was applied using 2aminoindan to produce the final product, N-(2-(N-(2,3-dihydro-1H-inden-2yl)sulfamoyl)phenyl)benzamide 33. Both final products from this synthetic approach
were characterized by 1H NMR and submitted for biological testing to compare SAR at
the two optimization sites.
The final goal was to synthesize derivatives with an N-aryl-sulfonamide in the
second amide carbonyl position based on the original anthranilamide structure. Initially, a
three step synthetic route
illustrated in Figure 16
starting sulfonylation of the
amine in anthranilic acid 34
by

reacting

with

benzenesulfonyl chloride 35
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to gave ortho-sulfonylaminobenzoic acid 36. Following the same procedures from prior
experiments, the product was then converted to an acid chloride using oxalyl chloride
followed by a final acylation step with 2-amino-1-methylbenzimidazole in acetonitrile.
TLC analysis of the reaction revealed no product, with starting material remaining
essentially unchanged. In view of the fact that the first trial of experiments were not
successful, an alternative route was then taken as displayed in Figure 17. Similar to the
procedure in Figure 14, the same type of reaction was carried out. The solubility of 39
was very limited in solvents
compatible with catalytic
hydrogenation. After multiple
attempts, the compound dissolved
in a 9:1 mixture of ethyl acetate
and methanol with heating and
the compound remained in solution after cooling. This allowed the nitro group to be
efficiently reduced, followed by acylation of intermediate 40 with benzenesulfonyl
chloride. In view of the effectiveness of the scheme outlined, it was repeated once more
with 2-aminoindan as the choice of amine to give the final sulfonamide derivative 42. All
intermediate and final compounds described were analyzed by 1H NMR to confirm
presence of the appropriate product before being sent for biological testing.
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Results and Discussion
Over the course of the project, a total of thirteen analogs were sent for biological
testing to analyze whether each compound showed activity for PDE11A inhibition. From
the thirteen compounds synthesized, nine of them are bisamide analogs while the
remaining four are sulfonamide derivatives as illustrated in Figure 18 which were
generated using ChemDraw. The molecular weight of the majority of the compounds fall
close 400 g/mol with a maximum of 406 g/mol, not far off from the desired value. TPSA
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takes into account the sum of surfaces of polar atoms within the compound where a lower
value corresponds to a better ability to penetrate the blood brain barrier. The TPSA for the
analogs synthesized ranges from 49 to 90 indicating the molecules have the capability of
permeating the cell membranes of cells and act on the receptors in the central nervous
system. Equally important, the cLogP characterizes a compounds hydrophilicity where a
lower value such as 3.5 is ideal. Amongst the compounds sent for testing, 18 shows
highest hydrophilicity with a value of 0.643 indicating notable absorption or permeation.
5FOA assays were utilized to test the compounds inhibition against
phosphodiesterase enzymes. All the
compounds were tested in a dose
response at final concentrations 0.5
to 62.5 µM with DMSO as the
negative control since it will not
produce any results. All analogs
were compared to 1, the
anthranilamide PDEllA inhibitor
discovered during the initial
screening, which was used as a
positive control. The first graph
shown in Figure 19 displays the
data for the activity of bisamide
analogs (17 through 24) for
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PDE11A inhibition. Majority of the compounds displayed no activity, resembling the
negative control except for compounds 17, 19, and 20 which presented weak inhibition
for PDE11A compared to 1. The next PDE11A response curve presents data generated for
the bisamide and sulfonamide analogs consisting of 2-aminoindan (27, 33, and 42).
Given that the compounds exhibit no activity for inhibition even at higher concentrations
and activities are almost identical to the negative control, suggests that these three
compounds are inactive as PDE11A inhibitors. The final response curve of Figure 19
displays data observed for
sulfonamide derivatives with 2amino-1-methylbenzimidazole, 30
and 41. The same trend was observed
as the previous plot where the
compounds displayed no inhibition
activity for PDE11A.
In addition to assessing
c o m p o u n d s a g a i n s t P D E 11 A
inhibition, each compound was also
tested for PDE10A inhibition, to
further provide information on the
selectivity of the analogs at hand
(Figure 20). Bisamide analogs 17 to
24 displayed no activity with the
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exception of 24 that showed weak inhibition. Comparatively, 24 did not exhibit
maximum activity for PDE11A inhibition indicating this analog is not as potent or
selective for PDE11A as desired yet further modification to optimizations site R1 may
improve these factors. As for the sulfonamide derivatives presented in the following two
graphs, only 30 and 41 show minor inhibition activity for PDE10A compared to the
positive control at increasing concentrations. As a whole, it is clear the bisamide analogs
with heterocyclic amines in position R1 were very weak to inactive for PDE11A and
PDE10A inhibition, therefore the analogs are neither selective or potent as desired.
Likewise, both sulfonamide derivatives with 2-aminoindan appeared to follow the same
trend as the bisamide analogs. With regards to the sulfonamide derivatives with
methylbenzimidazole, both showed no inhibition for PDE11A but displayed weak
inhibition for PDE10A indicating these derivatives did not improve selectivity.
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Conclusion and Further Studies
Overall, the aim of the project is to provide the foundation for discovery of a
novel PDE11A inhibitor with drug like characteristics. Phosphodiesterases play a role in
converting cyclic nucleotides into a nucleoside monophosphates, consequently
inactivating the signaling pathways of two key second messengers, cAMP and cGMP.
With all things considered, if able to inhibit PDE11A, it would then be possible to
increase the levels of second messengers in brain cells. It is important to note that
PDE11A is a potential drug target because it has the capacity to restore normal cyclic
nucleotide signaling in the brain caused by age related cognitive impairment without
affecting any other signaling in the brain. This is due to the fact that this isoform is
exclusively expressed in the ventral hippocampal formation of mice cells. Being that
there is no drug on the market capable of treating or preventing the mechanism that
causes memory loss, the discovery of a novel PDE11A inhibitor could possibly reverse or
prevent the effects of memory loss which affects millions of people worldwide. Certain
criteria should be met by the inhibitor such as good blood brain barrier penetration, water
solubility, metabolic stability, and hydrophilicity which can be assessed by TPSA, cLogP,
and efflux ratio [MDCK ratio 1:1].
By understanding the structure activity relationship between lead candidates from
preliminary data, specifically the anthranilamide 1 and phosphodiesterase, synthesis of
analogs was performed in hopes of obtaining greater potency and selectivity for PDE11A.
Modifications carried out solely in position R1 of the anthranilamide proved to be largely
to be very weak to inactive for PDE11A inhibition. Based on the results from the 5FOA
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assays, the starting bisamide does not appear to be a practical lead for discovery of
PDE11A inhibitors since no active analogs were identified. On the other hand,
sulfonamide derivatives with methylbenzimidazole are still a key interest even though
both analogs displayed weak to no inhibition in assays for both PDE11A and PDE10A.
More detailed research needs to take place prior to determining whether this approach is
useful in identifying a PDE11A inhibitor.
Provided that none of the bisamide or sulfonamide analogs proved to be active
PDE11A inhibitors, further research can be carried out by widening the characterization
of lead candidates. One option involves synthesizing further analogs based on the
anthranilamide 1 such as modifying position R1 with varying amines or R2 with
substituted phenyl heterocycles and/or replacing amide positions with sulfonamides.
Since an experimental procedure with suitable reaction conditions for synthesizing
sulfonamides in both positions has been determined, this permits rapid synthesis of these
analogs. Modifying these optimization sites individually or simultaneously will provide
further information on the structure activity relationship in the three key regions.
Additionally, an alternative approach may be taken where the focus of the project can be
switched to preparing analogs based on pyrimidinyl pyrrole 3 which showed to be a
selective PDE11 inhibitor during the initial screening. Given the limited information of
SAR, further modifications involving replacement of the phenyl with substituted phenyls
or short alkyls or replacing the amine with primary or secondary heterocycles can be
pursued. Taking everything into consideration, further optimizations of either 1 or 3
should give insight into developing a novel PDE11A inhibitor.
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Experimental Section
The solvents and reagents were purchased from commercial suppliers (Acros
Organics, Alfa Aesar, Combi-Blocks, Fisher Chemical, Sigma-Aldrich, TCI) and used
without further purification. The reactions were all monitored by thin layer
chromatography run on Silica XG TLC plates, aluminum backed, coated with silica gel
(200 um) and visualized under UV light (254 nm) with chemicals and stains. Crude
mixtures were purified either by recrystallization or by flash column chromatography
using CombiFlash RF+ with RediSep Rf columns ranging from 4 grams to 40 grams.
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker Spectrospin 400
MHz for 1H at room temperature with solvent peaks as reference. Chemical shifts are
reported in parts per million (ppm). The splitting patterns in 1H NMR data are reported in
the following order: multiplicity (s, singlet; d, doublet; dd, double doublet; t, triplet; m,
multiplet) and number of protons. LC-MS was performed on two instruments: an Advoin
expression CMS with Acquity UPLC H-class system and a Shimadzu where the samples
were run in methanol.
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General Procedures
i. 2-benzamidobenzoyl chloride 16:

In a 50 mL round bottom flask, 2-benzamidobenzoic acid (200.5 mg, 0.829 mmol, 1.0
mol equiv) and a catalytic amount of DMF (one drop) were suspended in methylene
chloride (5 mL). To the solution, oxalyl chloride (137.2 mg, 1.080 mmol, 200.5 μL, 1.3
mol equiv) was carefully added through a micropipette. The mixture was rapidly stirred
at room temperature under nitrogen for approximately three hours. In order to remove the
residual methylene chloride, the sample was concentrated producing a white powder and
placed on a high vacuum pump for an hour. The desired product was obtained in 92%
yield (200 mg, 0.077 mmol) and used without further purification.
ii. N-(2-(4-phenylpiperidine-1-carbonyl)phenyl)benzamide 17:

In a reaction vial, 2-benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.2 mol equiv)
was added to a solution of 4-phenyl piperidine (78.3 mg, 0.463 mmol, 1.0 mol equiv) and
triethylamine (54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in DMF (5 mL). The vial was
stirred in an oil bath heated to 80°C overnight. The following day, once the reaction was
cooled to room temperature, ethyl acetate (20 mL) was added to the resulting reaction
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mixture. The organic layer was washed with water (30 mL), then brine (10 mL) and dried
over sodium sulfate. The filtered and concentrated light brown solid was purified by flash
column chromatography on silica eluting with Hexane/EtOAc (6:1). The reaction yielded
50 mg (0.133 mmol, 34%).
1H

NMR (CDCl3): δ 1.71 (s, 3H, 1), δ 1.72 (s, 2H, 2), δ 2.79 (d, 2H, 3), δ 4.09 (s, 1H, 4),

δ 4.88 (s, 1H, 5), δ 7.15 - 7.26 (m, 7H, 6), δ 7.52 (m, 4H, 7), δ 7.90 (d, 2H, 8), δ 8.47 (d,
1H, 9), δ 10.05 (s, 1H, 10)
iii. 2-benzamido-N-(pyrazin-2-ylmethyl)benzamide 18:

Experimental procedure for 17 was repeated here.
2-aminomethyl pyrazine (54.4 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol,
40 μL, 1.4 mol equiv) in DMF (5 mL) gave 18 as a white solid. Purification by flash
column chromatography (95:5 DCM, Methanol) yielded 40 mg (0.120 mmol, 31%).
1H

NMR (CDCl3): δ 4.84 (s, 2H, 1), δ 7.09 (m, 1H, 2), δ 7.49 (m, 3H, 3), δ 7.68 (d, 1H,

4), δ 7.70 (s, 1H, 5), δ 8.00 (d, 2H, 6), δ 8.56 (s, 2H, 7), δ 8.72 (s, 1H, 8), δ 8.82 (d, 1H,
9), δ 12.14 (s, 1H, 10)
iv. N-(2-(3-benzylpyrrolidine-1-carbonyl)phenyl)benzamide 19:
To a reaction vial, 2-benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.2 mol equiv)
was added to a solution of 3-benzyl pyrrolidine (78.9 mg, 0.463 mmol, 1.0 mol equiv)
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and triethylamine (54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in acetonitrile (5 mL).
The reaction was placed in an oil bath heated to 80°C and stirred overnight. The
following day, ethyl acetate (25 mL) was added to the resulting reaction mixture. The
organic layer was washed with 1 N HCl (20 mL), then brine (20 mL) and dried over
sodium sulfate. The filtered and concentrated white solid precipitate was purified by flash
column chromatography on silica eluting with Hexane/EtOAc (3:1). The reaction yielded
91 mg (0.237 mmol, 62%).
1H

NMR (CDCl3): δ 1.65 (m, 1H, 1), δ 2.00 (d, 1H, 2), δ 2.42 (t, 1H, 3), δ 2.62 (m, 1H,

4), δ 2.72 (t, 1H, 5), δ 3.38 (m, 1H, 6), δ 3.60 (m, 2H, 7), δ 3.76 (m, 1H, 8), δ 7.08 - 7.28
(m, 6H, 9), δ 7.51 (m, 5H, 10), δ 7.99 (d, 2H, 11), δ 8.55 (d, 1H, 12), δ 10.83 (s, 1H, 13)
v. (S)-N-(2-(3-phenylpiperidine-1-carbonyl)phenyl)benzamide 20:

Experimental procedure for 19 was repeated here.
(S)-3-phenylpiperidine (91.5 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol,
40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 44 mg (0.115 mmol, 30%) of 20 as a
white powder.
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1H

NMR (CDCl3): δ 1.76 (m, 4H, 1), δ 2.08 (m, 1H, 2), δ 2.82 - 3.07 (d, 4H, 3), δ 4.03

(s, 1H, 4), δ 4.81 (s, 1H, 5), δ 7.20 (s, 2H, 6), δ 7.26 (m, 2H, 7), δ 7.51 (m, 5H, 8), δ
7.95 (t, 2H, 9), δ 8.47 (d, 1H, 10), δ 10.09 (s, 1H, 11)
vi. (R)-2-benzamido-N-(1-phenylethyl)benzamide 21:

Experimental procedure for 19 was repeated here.
D-(+)-alpha-methylbenzylamine (59 mg, 0.463 mmol, 1.2 mol equiv) and 2benzamidobenzoyl chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine
(54.5 mg, 0.540 mmol, 40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 57 mg (0.166
mmol, 43%) of 21 as a white precipitate.
1H

NMR (CDCl3): δ 1.64 (s, 3H, 1), δ 7.01 (s 1H, 2), δ 7.41 - 7.49 (m, 12H, 3), δ 8.00 (t,

2H, 4), δ 8.71 (s, 1H, 5), δ 11.99 (s, 1H, 6)
vii. (S)-2-benzamido-N-(1-phenylethyl)benzamide 22:

Experimental procedure for 19 was repeated here.
1-phenylpiperazine (75.1 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol,
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40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 48 mg (0.140 mmol, 36%) of 22 as
a white precipitate.
1H

NMR (CDCl3): δ 1.64 (s, 1H, 1), δ 6.89 (s, 1H, 2), δ 6.97 (t, 1H, 3), δ 7.36 - 7.49 (m,

11H, 4), δ 7.99 (d, 2H, 5), δ 8.69 (s, 1H, 6), δ 11.97 (s, 1H, 7)
viii. N-(2-(4-phenylpiperazine-1-carbonyl)phenyl)benzamide 23:

Experimental procedure for 19 was repeated here.
2-aminobenzothiazole (70 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol,
40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 75 mg (0.195 mmol, 51%) of 23 as
a white powder.
1H

NMR (DMSO): δ 3.19 (s, 4H, 1), δ 3.74 - 3.92 (dd, 4H, 2), δ 6.93 (m, 3H, 3), δ 7.16

(m, 1H, 4), δ 7.27 (m, 3H, 5), δ 7.49 (m, 4H, 6), δ 7.94 (t, 2H, 7), δ 8.49 (d, 1H, 8), δ
10.11 (s, 1H, 9)
ix. 2-benzamido-N-(benzo[d]thiazol-2-yl)benzamide 24:

Experimental procedure for 19 was repeated here.
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2-aminobenzothiazole (70 mg, 0.463 mmol, 1.2 mol equiv) and 2-benzamidobenzoyl
chloride (100 mg, 0.386 mmol, 1.0 mol equiv) with triethylamine (54.5 mg, 0.540 mmol,
40 μL, 1.4 mol equiv) in acetonitrile (5 mL) yielded 30 mg (0.081 mmol, 21%) of 24 as a
white solid precipitate.
1H

NMR (DMSO): δ 7.32 (m, 3H, 1), δ 7.45 (t, 1H, 2), δ 7.56 - 7.72 (m, 7H, 3), δ 7.95

(d, 2H, 4), δ 12.17 (s, 1H, 5)
LC/MS: Calc. For C21H15N3O2S : 373.09; found 374
x. N-(2,3-dihydro-1H-inden-2-yl)-2-nitrobenzamide 25:

To a solution of 2-aminoindan (200 mg, 1.18 mmol, 1.0 mol equiv) in pyridine (5 mL)
was added 2-nitrobenzenesulfonyl chloride (315 mg, 1.42 mmol, 1.2 mol equiv). The
reaction was stirred at room temperature for approximately four hours. The reaction was
then poured into 1 N HCl (20 mL) where the organic layer was extracted using ethyl
acetate (45 mL). Following this, the organic layer was washed with brine (20 mL), dried
over sodium sulfate, filtered, and concentrated. The product was recrystallized in DCM/
hexane to give pure yellow crystals with 54% yield (180.7 mg, 0.641 mmol).
1H

NMR (Acetone-d6): δ 3.08 (dd, H, 1), δ 3.37 (dd, H, 2), δ 4.85 (m, H, 3), δ 7.20 -

7.27 (dd, H, 4), δ 7.68 - 7.81 (m, H, 5), δ 8.05 (d, H, 6)
xi. 2-amino-N-(2,3-dihydro-1H-inden-2-yl)benzamide 26:
To a Parrbottle, Pd/C (20 mg, 20% by weight) was added followed by the slow addition
of methanol (10 mL) and 25 (100 mg, 0.355 mmol). The bottle was placed in the
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ParrShaker at 28 psi overnight. The following day, the contents of the flask were poured
into a filter funnel containing celite and washed with methanol. To assure desired product
was produced, ninhydrin test was utilized resulting in a ninhydrin positive TLC plate. The
final product was filtered and concentrated to give a tan solid in 47% yield (45 mg, 0.168
mmol).
1H

NMR (Acetone-d6): δ 3.01 (dd, 2H, 1), δ 3.28 (dd, 2H, 2), δ 4.82 (m, 1H, 3), δ 6.26

(s, 2H, 4), δ 6.46 (t, 1H, 5), δ 6.72 (d, 1H, 6), δ 7.14 - 7.20 (m, 5H, 7), δ 7.48 (d, 1H, 8), δ
7.75 (s, 1H, 9)
xii. 2-benzamido-N-(2,3-dihydro-1H-inden-2-yl)benzamide 27:

The benzoyl chloride (52 mg, 0.373 mmol, 2 mol equiv) was added to a solution of 26
(50 mg, 0186 mmol, 1 mol equiv) with triethylamine (47 mg, 0.465 mmol, 2.5 mol equiv)
in DMF (3 mL). The reaction proceeded to be stirred at room temperature for two hours.
Subsequently, the reaction was poured into water (10 mL) and the organic layer was
extracted using ethyl acetate (30 mL). The organic layer was then washed with 1 N HCl
(20 mL), sodium bicarbonate (20 mL), and brine (20 mL). Organic layer was then dried
over sodium sulfate, filtered, and concentrated. The crude product was purified through
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flash column chromatography (2:1 Hexane/EtOAc) to yield 29 mg of yellow crystals
(0.081 mmol, 44%).
1H

NMR (Acetone-d6): δ 3.01 (dd, 2H, 1), δ 3.44 (dd, 2H, 2), δ 4.96 (m, 1H, 3), δ 7.06 -

7.16 (m, 5H, 4), δ 7.59 (m, 4H, 5), δ 7.86 (d, 1H, 6), δ 8.06 (t, 2H, 7), δ 8.42 (a, 1H, 8), δ
8.87 (d, 1H, 9)
LC/MS: Calc. For C23H20N2O2 : 356.15; found 357.5
xiii. N-(1-methyl-1H-benzoimidazol-2-yl)-2-nitrobenzenesulfonamide 28:

In a round bottom flask, 2-amino-1-methylbenzimidazole (100 mg, 0.680 mmol, 1.0 mol
equiv) was dissolved in chloroform (10 mL) and treated successively 2nitrobenzenesulfonyl chloride (300 mg, 1.360 mmol, 2.0 mol equiv). To the solution,
triethylamine (171 mg, 1.700 mmol, 125 μL, 2.5 mol equiv) and DMAP (25 mg, 0.200
mmol, 0.3 mol equiv) were added. The mixture was refluxed overnight under nitrogen in
an oil bath heated to 65°C. The following day, the reaction was poured into DCM (10mL)
where the organic layer was washed with 1 N HCL (30 mL) and brine (10 mL), dried
over sodium sulfate, filtered, and concentrated. The crude product was purified using
flash column chromatography (2:1 Hexane/EtOAc) to give a yellow solid precipitate. The
desired product was acquired in 34% yield (76.6 mg, 0.231 mmol).
1H

NMR (Acetone-d6): δ 3.56 (s, 3H, 1), δ 7.29 (m, 2H, 2), δ 7.43 (d, 1H, 3), δ 7.54 (d,

1H, 4), δ 7.78 (t, 2H, 5), δ 8.16 (m, 1H, 6), δ 8.32 (d, 1H, 7)
xiv. 2-amino-N-(1-methyl-1H-benzo[d]imidazol-2-yl)benzenesulfonamide 29:
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In a Parbottle, Pd/C (40 mg, 20% by weight) was added followed by the addition of
acetic acid (10 mL) and 28 (200 mg, 0.602 mmol). The bottle was placed in the
ParrShaker at 40 psi overnight. The contents of the flask were poured into a filter funnel
containing celite and washed with excess acetic acid, then concentrated down. Toluene
was added to form an azeotrope with acetic acid before being evaporated off which was
repeated three times with 10 mL of toluene. To insure the desired product was produced,
ninhydrin test was used resulting in a ninhydrin positive TLC plate. Reaction yielded 100
mg of tan solid product (0.276 mmol, 55%).
1H

NMR (Acetone-d6): δ 3.32 (s, 3H, 1), δ 6.58 (t, 1H, 2), δ 6.68 (t, 1H, 3), δ 6.81 (d,

1H, 4), δ 6.87 (d, 1H, 5), δ 7.44 (d, 1H, 6), δ 7.76 (dd, 2H, 7), δ 7.84 (d, 1H, 8)
xv. N-(2-(N-(1-methyl-1H-benzo[d]imidazol-2-yl)sulfamoyl)phenyl)benzamide 30:

In a reaction vial, 2-(N-(1-methyl-1H-benzo[d]imidazol-2-yl)sulfamoyl)benzenaminium
(200 mg, 0.552 mmol, 1.0 mol equiv) was dissolved in acetonitrile ( 5 mL) and treated
successively with triethylamine (167 mg, 1.657 mmol, 120 μL, 3 mol equiv), DMAP (40
mg, 20% by weight), and benzoyl chloride (232 mg, 1.657 mmol, 280 μL, 3.0 mol
equiv). The vial was sealed and placed in a 65°C to stir overnight. Following this, the
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reaction was poured into ethyl acetate (10mL) where the organic layer was washed with
water (15 mL), sodium bicarbonate (10 mL), and brine (10 mL). Organic layer was dried
over sodium sulfate, filtered, and concentrated. The crude product was purified using
flash column chromatography (1:1 Hexane/EtOAc) to give a tan solid precipitate. The
desired product was acquired in 31% yield (70 mg, 0.172 mmol).
1H

NMR (Acetone-d6): δ 3.35 (s, 3H, 1), δ 7.21 (m, 3H, 2), δ 7.31 (d, 1H, 3), δ 7.45 (dd,

1H, 4), δ 7.60 (m, 4H, 5), δ 8.03 (d, 1H, 6), δ 8.17 (dd, 2H, 7), δ 8.65 (d, 1H, 8), δ 10.48
(s, 1H, 9), δ 11.19 (s, 1H, 10)
LC/MS: Calc. For C21H18N4O3S : 406.11; found 407
xvi. N-(2,3-dihydro-1H-inden-2-yl)-2-nitrobenzenesulfonamide 31:

Experimental procedure for 25 was repeated here except in an oil bath heated to 55°C.
2-aminoindan (200 mg, 1.18 mmol, 1.0 mol equiv) and 2-nitrobenzenesulfonyl chloride
(315 mg, 1.42 mmol, 1.2 mol equiv) in pyridine (5 mL) yielded 288.6 mg of pure yellow
crystals (0.908 mmol, 77%).
1H

NMR (Acetone-d6): δ 2.99 (dd, 2H, 1), δ 3.19 (dd, 2H, 2), δ 4.45 (m, 1H, 3), δ 7.18

(m, 4H, 4), δ 7.99 (m, 3H, 5), δ 8.27 (d, 1H, 6)
xvii. 2-amino-N-(2,3-dihydro-1H-inden-2-yl)benzenesulfonamide 32:
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In a 3-neck round bottom flask, the weighed out Pd/C (20 mg, 20% by weight) was added
followed by the slow addition of methanol (14 mL) and 31 (100 mg, 0.315 mmol) under
nitrogen. A balloon apparatus was attached in place of nitrogen, then the system was
flushed three times under vacuum. Allowed the solution to stir for approximately two
hours. To assure desired product was produced, ninhydrin test was utilized resulting in a
ninhydrin positive TLC plate. Then, the contents of the flask were poured into a filter
funnel containing celite and washed with methanol. The final product was filtered and
concentrated to give a tan solid in 65% yield (62 mg, 0.204 mmol).
1H

NMR (Acetone-d6): δ 2.85 (dd, 2H, 1), δ 2.99 (dd, 2H, 2), δ 4.02 (m, 1H, 3), δ 5.68

(s, 2H, 4), δ 6.72 (t, 1H, 5), δ 6.90 (s, 1H, 6), δ 6.92 (d, 1H, 7), δ 7.10 (m, 4H, 8), δ 7.32
(t, 1H, 9), δ 7.68 (d, 1H, 10)
xviii. N-(2-(N-(2,3-dihydro-1H-inden-2-yl)sulfamoyl)phenyl)benzamide 33:

A solution of 32 (50 mg, 0.164 mmol, 1 mol equiv) and benzoyl chloride (28 mg, 0.197
mmol, 1.2 mol equiv) in pyridine (2 mL) were stirred in an oil bath heated to 65°C
overnight. The following day, the reaction was poured into 1 N HCl (20 mL) where the
organic layer was extracted using ethyl acetate (30 mL). Following this, the organic layer
was washed with excess 1 N HCl (20 mL), sodium bicarbonate (20 mL), and brine (20
mL). Organic layer was then dried over sodium sulfate, filtered, and concentrated. The
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crude product was purified through flash column chromatography (2:1 Hexane/EtOAc) to
yield 17 mg of white powder (0.043 mmol, 25%).
1H

NMR (Acetone-d6): δ 2.78 (dd, 2H, 1), δ 3.01 (dd, 2H, 2), δ 4.26 (m, 1H, 3), δ 7.07

(m, 4H, 4), δ 7.33 (t, 1H, 5), δ 7.54 (m, 2H, 6), δ 7.62 (d, 1H, 7), δ 7.74 (t, 1H, 8), δ 7.99
(d, 1H, 9), δ 8.12 (d, 1H, 10), δ 8.73 (d, 1H, 11)
LC/MS: Calc. For C22H20N2O3S : 392.12; found 393
xix. N-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-nitrobenzamide 39:

2-amino-1-methylbenzimidazole (265 mg, 1.802 mmol, 1.0 mol equiv) was dissolved in
pyridine (6 mL) followed by the addition of 2-nitrobenzoyl chloride (400 mg, 2.162
mmol, 1.2 mol equiv). The contents of the flask were stirred at 60°C for around four
hours. The pyridine was then evaporated off and the remaining contents were dissolved
into ethyl acetate (20 mL) where the organic layer was extracted using ethyl acetate (45
mL). The organic layer was washed with sodium bicarbonate (20 mL) and brine (20 mL).
The solid material was filtered out and organic layer was dried over sodium sulfate,
filtered, and concentrated. Purification of the crude product was completed on a flash
column chromatography (2:1 Hexane/EtOAc) to give a pure white solid precipitate with
30% yield (160 mg, 0.541 mmol).
1H

NMR (DMSO): δ 3.47 (s, 3H, 1), δ 7.87 (d, 1H, 2), δ 7.46 - 7.59 (m, 3H, 3), δ 7.67

(m, 1H, 4), δ 7.82 (m, 1H, 5), δ 8.11 (d, 1H, 6), δ 8.39 (d, 1H, 7)

45
LC/MS: Calc. For C15H12N4O3 : 296.09; found 297.6
xx. 2-amino-N-(1-methyl-1H-benzo[d]imidazol-2-yl)benzamide 40:

39 (200 mg, 0.676 mmol) was dissolved in a 9:1 ethyl acetate/methanol solution (50 mL)
in a 125 Erlenmeyer flask using a heat gun. Pd/C (40 mg, 20% by weight) was added to a
Parbottle followed by the addition of the above solution. The bottle was then placed in
the ParrShaker at 40 psi overnight. The next day, the contents of the flask were poured
into a filter funnel containing celite and washed with excess methanol. To assure the
correct product was produced, ninhydrin test was used resulting in a ninhydrin positive
TLC plate. The final product was concentrated to give a white solid in 95% yield (190
mg, 0.714 mmol).
1H

NMR (Acetone-d6): δ 3.82 (s, 3H, 1), δ 6.53 (t, 1H, 2), δ 7.31 (t, 1H, 3), δ 7.37 (m,

1H, 4), δ 7.52 (d, 1H, 5), δ 7.65 (d, 1H, 6), δ 7.78 (t, 1H, 7), δ 8.39 (dd, 1H, 8), δ 8.56 (d,
1H, 9)
xxi. N-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-(phenylsulfonamido)benzamide 41:

Experimental procedure for 30 was repeated here.

46
40 (50 mg, 0.1879, 1 mol equiv) treated with triethylamine (57 mg, 0.5639 mmol, 41 μL,
3 mol equiv), DMAP (13 mg, 25% by weight), and sulfonyl chloride (100 mg, 0.5639
mmol, 137 μL, 3.0 mol equiv) in acetonitrile (4 mL) produced 35 mg of a white solid
precipitate (0.086 mmol, 46%).
1H

NMR (Methanol): δ (s, 3H, 1), δ 7.33 - 7.43 (m, 4H, 2), δ 7.48 - 7.56 (m, 3H, 3), δ

7.78 (d, 1H, 4), δ 7.61 (d, 1H, 5), δ 7.79 (q, 2H, 6), δ 8.32 (d, 1H, 7), δ 8.57 (d, 1H, 8)
LC/MS: Calc. For C21H18N4O3S : 406.11; found 407
xxii. N-(2,3-dihydro-1H-inden-2-yl)-2-(phenylsulfonamido)benzamide 42:

Experimental procedure for 27 was repeated here except with sulfonyl chloride.
Compound 26 (50 mg, 0.186 mmol, 1.0 mol equiv) mixed with triethylamine (47 mg,
0.465 mmol, 2.5 mol equiv) and benzoyl chloride (66 mg, 0.373 mmol, 2 mol equiv) in
DMF (3 mL) yielded 9 mg of pure white crystals (0.023 mmol, 12%).
1H

NMR (Acetone-d6): δ 3.38 (dd, 2H, 1), δ 3.55 (dd, 2H, 2), δ 4.73 (m, 1H, 3), δ 7.02

(t, 1H, 4), δ 7.16 (, 4H, 5), δ 7.48 (t, 1H, 6), δ 7.52 (m, 4H, 7), δ 7.69 (d, 1H, 8), δ 7.76
(m, 1H, 9), δ 8.31 (d, 1H, 10)
LC/MS: Calc. For C22H20N2O3S : 392.12; found 393.6
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NMR Spectra
i. Compound 17

ii. Compound 18
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iii. Compound 19

iv. Compound 20
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v. Compound 21

vi. Compound 22
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vii. Compound 23

viii. Compound 24
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ix. Compound 25

x. Compound 26
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xi. Compound 27

xii. Compound 28
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xii. Compound 29

xiv. Compound 30
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xv. Compound 31

xvi. Compound 32
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xvii. Compound 33

xviii. Compound 39
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xix. Compound 40

xx. Compound 41
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xxi. Compound 42
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Mass Spectra
i. Compound 24

ii. Compound 27

iii. Compound 30
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iv. Compound 33

v. Compound 39

vi. Compound 41
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vii. Compound 42

